Find Funding Opportunities

The purpose of this FOA from NIH, CDC, and FDA is to invite eligible United States small business concerns (SBCs) to submit SBIR Phase I, Phase II, and Fast-Track grant applications through Grants.gov. SBIR Fast-Track grant applications are accepted by the NIH ONLY.

The purpose of this FOA from NIH is to invite eligible United States small business concerns (SBCs) to submit STTR Phase I, Phase II, and Fast-Track grant applications through Grants.gov. (CDC and FDA do not accept STTR grant applications).

This initiative is intended to stimulate the commercial development of novel radioligands for positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging in human brain, and to incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies. The NIH institutes listed in this FOA are specifically interested in the development of radioligands for molecular targets (e.g., receptors, cell adhesion molecules, intracellular messengers, and disease related proteins) that are of broad interest to the scientific community. These radiotracers will be used for neuroimaging as well as potential biological markers and surrogate endpoints for translational and clinical research, drug discovery and development, and clinical trials. Also appropriate for this FOA are applications proposing research and development of new technologies for radiotracer development.

This initiative is intended to stimulate the commercial development of novel radioligands for positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging in human brain, and to incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies. The NIH institutes listed in this FOA are specifically interested in the development of radioligands for molecular targets (e.g., receptors, cell adhesion molecules, intracellular messengers, and disease related proteins) that are of broad interest to the scientific community. These radiotracers will be used for neuroimaging as well as potential biological markers and surrogate endpoints for translational and clinical research, drug discovery and development, and clinical trials. Also appropriate for this FOA are applications proposing research and development of new technologies for radiotracer development.

- The goals of NIH-supported career development programs are to help ensure that diverse pools of highly trained scientists are available in adequate numbers and in appropriate research areas to address the Nation's biomedical, behavioral, and clinical research needs. - The purpose of the Mentored Research Scientist Development Award (K01) is to provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Awards are not renewable, nor are they transferable from one principal investigator to another. - The K01 application may be submitted on behalf of the candidate (principal investigator) by any domestic for-profit or non-profit institution/organization, or public or private institutions, such as universities, colleges, hospitals and laboratories. Foreign institutions are not eligible to apply. - Candidates must be U.S. citizens or non-citizen nationals, or an individual lawfully admitted for permanent residence, who hold a research or health-professional doctoral degree or its equivalentand can commit a minimum of 75% of full-time professional effort conducting research and relevant career development activities specified in the application.Receipt of prior support may impact on eligibility. - The candidate must demonstrate and justify the need for a three, four, or five-year period of additional supervised research experience. Planning, direction, and execution of the proposed career development program and research project will be the responsibility of the candidate and his/her mentor. - The proposed career development experience must be in a research area new to the applicant and/or one in which an additional supervised research experience will substantially augment the research capabilities of the applicant. - The candidate should provide a plan and proposed timeline for achieving independent research support by the end of the award period. - The amount funded as salary for a career development award is not uniform throughout the NIH participating Institutes and Centers (ICs); therefore, the applicant is strongly advised to contact the relevant IC for any distinct guidelines, requirements, and allowable funds (see website referenced in Section VII for IC contacts). - The total amount to be awarded and the number of anticipated awards will depend upon the quality, duration, and costs of the applications received as determined by the peer review process, available funds and program priorities. - The candidate for this K01 award may not concurrently apply for or have an award pending for another NIH career development award. Up to two revisions of an application will be accepted. - Applications must be submitted on or before the receipt dates described at http://grants.nih.gov/grants/funding/submissionschedule.htm. - Special Note:The participating NIH ICs may have distinctive guidelines, requirements, and funding amounts for this announcement in order to accommodate the career development needs of researchers working in fields related to their specific research missions. Candidates are therefore strongly encouraged to contact the staff person in the relevant Institute or Center listed under Section VII prior to preparing an application to discuss issues of eligibility, program relevance, and review the specific provisions of this award. - See Section IV for application and submission information. - Telecommunications for the hearing impaired is available at: TTY 301-451-0088

- This RFA is an initiative of the NIH Blueprint for Neuroscience Research (http://neuroscienceblueprint.nih.gov), a trans-NIH partnership to accelerate neuroscience research. Fifteen Institutes and Centers are participating in the Neuroscience Blueprint. This RFA will be administered by the NINDS on behalf of the Neuroscience Blueprint. - Neuroscience Blueprint Interdisciplinary Center Core Grants will support centralized resources and facilities shared by neuroscience investigators. Each Center will be composed of one or more research cores, each of which will enrich the effectiveness of ongoing research, and promote new research directions. - Applicants may request up to $1.5 million per year in direct costs. The total project period for an application submitted in response to this RFA may not exceed 5 years. - This RFA will use the NIH Center Core Grants (P30) award mechanism. - Eligible organizations include for-profit and non-profit organizations, public or private institutions, such as universities, colleges, hospitals, and laboratories, units of State and local governments, eligible agencies of the Federal government, units of State or local Tribal governments, domestic institutions, and faith-based or community-based organizations. - Eligible Principal Investigators include any individuals with the skills, knowledge, and resources necessary to carry out the proposed research. - An applicant organization is eligible for a maximum of one Neuroscience Blueprint Interdisciplinary Center Core Grant. Only one application will be reviewed from a single applicant organization. - See Section IV.1 for application materials. - Telecommunications for the hearing impaired is available at: TTY 301-451-0088

- This Program Announcement (PA) encourages investigator-initiated applications designed to exploit the power of Xenopus as a vertebrate model for biomedical research. Applications are welcome proposing to develop new tools or genetic or genomic resources of high priority to the Xenopus community that will advance the detection and characterization of genes, pathways, and phenotypes of interest in development, organogenesis, and in cell biological processes, such as cell division, signaling and migration. - Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards made will depend upon the numbers, quality, duration, and costs of the applications received. - This PA will use the NIH individual research project grant (R01) award mechanism. - Eligible organizations include for-profit or non-profit organizations; public or private institutions, such as universities, colleges, hospitals, and laboratories; units or State and local government; eligible agencies of the Federal government; and, domestic or foreign institutions. - Eligible principal investigators include any individual with the skills, knowledge, and resources necessary to carry out the proposed research. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs. - Applications must be prepared using the most recent version of the PHS 398 research grant application instructions and forms available at http://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive format. For further assistance contact GrantsInfo, Telephone (301) 435-0714, Email: Grantsinfo@nih.gov. - Telecommunications for the hearing impaired is available at: TTY 301-451-0088

- The goal of this RFA is to improve the efficiency of germline transmission of C57BL/6 ES lines to an extent that permits the use of C57BL/6 ES cell for high throughput gene targeting and the efficient production of C57BL/6 mice carrying a null mutation. - Up to $1.6 million per year for three years is to be awarded through this RFA. - It is anticipated that 1 to 3 awards will be made. - It is anticipated the awards will be funded in July, 2006 for three years. - Awards will be made using the Cooperative Agreement (U01) mechanism. - Eligible organizations include for-profit or non-profit organizations; public or private institutions, such as universities, colleges, hospitals, and laboratories; units of State and local governments; eligible agencies of the Federal government, domestic or foreign; NIH Intramural laboratories may participate as collaborators. Applicants for this RFA must have a proven track record of producing or developing existing ES lines, preferably from C57BL/6 mice, and have themselves or their collaborators used such lines to create mutant germline competent ES cells by targeted, gene trap or transposon mutagenesis. Experience must support the proposed goals to develop a robust ES cell line(s). Documentation of this track record must be included. - Eligible principal investigators with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with his/her institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs. - Applicants may submit more than one application, provided they are scientifically distinct. - Investigators who applied for the RFA, "Completion of a Comprehensive Mouse Knockout Resource" (RFA-HG-05-007.) are encouraged to apply. - See Section IV.1 for application materials. - Telecommunications for the hearing impaired is available at: TTY 301-451-0088.

- This funding opportunity invites applications to support collaborative research between mental health specialists and neurological specialists dedicated to understanding the neurobiology relevant to the etiology and treatment of comorbid mental and neurological disorders. - The participating ICs intend to commit approximately $3.5M in FY 2006. - The anticipated number of awards is 6-10 grants. - This RFA will use the NIH Research Project Grant (R01), Small Research Grant (R03), and Exploratory/Developmental Grant (R21), and competing supplemental award mechanisms. - Eligible organizations include: for-profit or non-profit organizations; public or private institutions, such as universities, colleges, hospitals, and laboratories; units of State and local governments; eligible agencies of the Federal government; and domestic or foreign institutions/organizations. - Eligible principal investigators include any individual with the skills, knowledge, and resources necessary to carry out the proposed research. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs. - Applicants may submit more than one application, provided they are scientifically distinct. - See Section IV.1 for application materials. - Telecommunications for the hearing impaired is available at: TTY 301-451-0088

- The ultimate aim of the Knockout Mouse Project is to generate a null-mutant mouse resource comprising a null mutation marked with a reporter of high utility for each gene in mouse strain C57BL/6. The purpose of this RFA is to make maximum progress toward this goal using gene targeting, transposon-mediated mutagenesis or gene trapping. - Up to $50 million in total costs over 5 years is to be awarded through this RFA. - It is anticipated that 1 to 4 awards will be made. - It is anticipated that the awards will be funded in July 2006. - Awards will be made using the Cooperative Agreement (U01) mechanism. - Eligible organizations include for-profit organizations; non-profit organizations; public or private institutions, such as universities, colleges, hospitals, and laboratories; eligible agencies of the Federal government; domestic and foreign Institutions. - Eligible principal investigators with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs. - Applicants may submit more than one application, provided they are scientifically distinct. - See Section IV.1 for application materials. - Telecommunications for the hearing impaired is available at: TTY 301-451-0088.